Protection against feline leukemia by vaccination with a subunit vaccine.
An effective vaccine against feline leukemia virus infection has been developed by the collection and concentration of tissue culture medium harvested from a tumor cell line. Lymphoid cells were grown to near saturation density in a normal growth medium and then transferred to a serum-free medium. The serum-free medium was collected, concentrated, and evaluated for its vaccine potential. Cats receiving the vaccine emulsified in complete Freund adjuvant developed high antiviral and antitumor titers and were protected (81%) against virus challenge. Cats receiving the vaccine without an adjuvant developed lower antibody levels and lower protection (53%) from viremia. Age-matched and litter-matched controls developed no antibody to test antigens before the challenge, and 100% became persistently viremic after the challenge. Vaccination with the soluble tumor cell antigen vaccine proved successful in preventing the induction of feline leukemia virus infection.
D000276:Adjuvants, Immunologic; D000367:Age Factors; D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D002415:Cats; D005256:Leukemia Virus, Feline / Q000276:immunology*; D007942:Leukemia, Experimental / Q000517:prevention & control*; D008565:Membrane Proteins / Q000276:immunology; D014611:Vaccination; D014764:Viral Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D008565:Membrane Proteins; D014764:Viral Proteins; D014765:Viral Vaccines